An amended 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics Inc (NASDAQ:ACRS), decreasing its stake in the company to 1.53 million shares, which account for 7.1% of the stock’s float. As per its 13F filing for the end of June, RA Capital Management’s stake consisted of 2.63 million common shares.
Aclaris Therapeutics Inc (NASDAQ:ACRS) is a clinical-stage pharmaceutical company that works on producing various therapeutics for treating dermatological problems. Over the past 12 months, the company’s stock has gained an outstanding 122.81%. In its financial report for the second quarter of 2016, Aclaris Therapeutics disclosed a net loss of $12.87 million and a net loss per share of $0.62, which compares to a net loss of $2.59 million and a net loss per share of $1.52 for the same period of the previous year. Recently, JMP Securities initiated coverage on Aclaris Therapeutics’ stock, placing an ‘Outperform’ rating on it and a price target of $34.
As per our hedge fund database, four investors that we track were long Aclaris Therapeutics Inc (NASDAQ:ACRS) at the end of June, same as a quarter earlier. Some of the bullish investors aside from RA Capital Management encompassed Kris Jenner, Gordon Bussard, and Graham Mcphail’s Rock Springs Capital Management, which held a position worth $18.47 million, and Bihua Chen’s Cormorant Asset Management, with a position valued at $16.65 million.
Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| RA Capital Management | 0 | 1,530,020 | 0 | 1,530,020 | 1,530,020 | 7.1% |
| Peter Kolchinsky | 0 | 1,530,020 | 0 | 1,530,020 | 1,530,020 | 7.1% |
| RA Capital Healthcare Fund | 0 | 1,304,714 | 0 | 1,304,714 | 1,304,714 | 6.1% |
Follow Peter Kolchinsky's RA Capital Management
Page 1 of 8 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. 2)*
Aclaris Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per
share
(Title of Class of Securities)
00461U105
(CUSIP Number)
September 26, 2016
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
